334 related articles for article (PubMed ID: 37834408)
21. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.
Waldron JS; Yang I; Han S; Tihan T; Sughrue ME; Mills SA; Pieper RO; Parsa AT
J Clin Neurosci; 2010 Dec; 17(12):1543-7. PubMed ID: 20822910
[TBL] [Abstract][Full Text] [Related]
22. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
[TBL] [Abstract][Full Text] [Related]
24. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
25. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
26. Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling.
Wu Y; Li Z; Zhang L; Liu G
Med Sci Monit; 2019 Oct; 25():7383-7390. PubMed ID: 31575848
[TBL] [Abstract][Full Text] [Related]
27. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
28. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
[TBL] [Abstract][Full Text] [Related]
30. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
Agnihotri S; Gugel I; Remke M; Bornemann A; Pantazis G; Mack SC; Shih D; Singh SK; Sabha N; Taylor MD; Tatagiba M; Zadeh G; Krischek B
J Neurosurg; 2014 Dec; 121(6):1434-45. PubMed ID: 25245477
[TBL] [Abstract][Full Text] [Related]
31. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
[TBL] [Abstract][Full Text] [Related]
32. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
[TBL] [Abstract][Full Text] [Related]
33. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Singh P; Kumar V; Gupta SK; Kumari G; Verma M
Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
[TBL] [Abstract][Full Text] [Related]
34. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
[TBL] [Abstract][Full Text] [Related]
35. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
36. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
[TBL] [Abstract][Full Text] [Related]
37. Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities.
Li T; Wang G
Int J Mol Sci; 2014 Oct; 15(10):18856-91. PubMed ID: 25334061
[TBL] [Abstract][Full Text] [Related]
38. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
Newton HB
Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
[TBL] [Abstract][Full Text] [Related]
39. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
40. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
